Ribon Therapeutics
Clinical-stage biotechnology company developing precision therapeutics that target stress-related biological pathways in cancer and inflammation, with lead candidates RBN-2397 (PARP7 inhibitor) and RBN-3143 (immunology program).
- Company typePrivate
- Founded2015
- HeadquartersCambridge, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Ribon Therapeutics does
Ribon Therapeutics is a clinical-stage biotechnology company developing precision medicine therapeutics that target stress-related biological pathways in cancer and inflammation. Founded in 2015 and headquartered in Cambridge, Massachusetts, the company's scientific premise is that modulating cellular stress support pathways represents a differentiated mechanism for treating oncology and immunology indications. Its lead clinical program is RBN-2397, a PARP7 inhibitor for cancer, and its second clinical-stage program, RBN-3143, is being developed for immunology applications. Both candidates are positioned as precision interventions in stress-pathway biology and constitute the entirety of Ribon's disclosed clinical pipeline.
The company is privately held and pre-revenue, operating under a standard clinical-stage biotech model in which operations are funded by equity capital and strategic corporate investment. Cumulative disclosed funding totals approximately $259 million across rounds from 2015 through 2023, including seed and Series A rounds in 2015–2016, a $20 million round in 2017, a $65 million Series B in January 2019 led by Novartis Venture Fund, a $65 million Series C in June 2021 co-led by Deerfield Management and U.S. Venture Partners, a $50 million financing from K2 HealthVentures in April 2022, an SEC-registered $25 million offering in December 2022, and a $25 million strategic investment from Pfizer announced in January 2023. Investor participation spans leading healthcare venture firms (Deerfield, U.S. Venture Partners, The Column Group, Euclidean Capital, Osage University Partners) and corporate venture arms of major pharma (AbbVie, Bristol-Myers Squibb, Johnson & Johnson Innovation, Novartis Venture Fund, Takeda Ventures, Pfizer, Google Ventures).
Ribon retains full control over its pipeline and relies on strategic pharma collaborations rather than direct product distribution. The Pfizer collaboration exemplifies this model: capital and advisory support flow to Ribon in exchange for development collaboration on RBN-2397 and RBN-3143, with Ribon maintaining pipeline autonomy. Headcount of 11–50 employees reflects the company's focused clinical-stage scale, and pricing details are not publicly disclosed because no therapeutic candidates have reached commercialization. The intended exit pathways consistent with this model are out-licensing, co-development partnerships, or acquisition by a larger pharmaceutical company.
Ribon Therapeutics firmographics
Firmographics- Name
- Ribon Therapeutics
- Legal name
- Ribon Therapeutics, Inc.
- Website
- https://ribontx.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Clinical-stage biotechnology company developing precision therapeutics that target stress-related biological pathways in cancer and inflammation, with lead candidates RBN-2397 (PARP7 inhibitor) and RBN-3143 (immunology program).
- Ownership category
- akta.pro rank
Ribon Therapeutics industry classification
Industry- Product category
- Clinical-stage Oncology Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- mRNA Therapeutics (vaccines, protein replacement, immuno-oncology) (HLAAADAA)
Keywords
Where Ribon Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Ribon Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations
Distribution channels1 record
Marketing channels2 records
Ribon Therapeutics product offering
Product offeringCore offering
Ribon Therapeutics is a clinical-stage biotechnology company developing precision medicines that target stress response pathways in cancer and inflammatory diseases. Its lead clinical candidates are RBN-2397, a first-in-class PARP7 inhibitor, and RBN-3143, advancing novel monoPARP-targeted therapies toward patients with cancer and inflammatory conditions.
Product overview
Ribon Therapeutics is a biotechnology company developing a precision medicine pipeline targeting stress-related biological pathways in cancer and inflammation. The company's clinical programs include RBN-2397, a PARP7 inhibitor for cancer treatment, and RBN-3143, an immunology program, both targeting stress support pathways.
Differentiator
Problem solved
Functional benefit
Products and services
- RBN-2397 RBN-2397 is a first-in-class small molecule inhibitor of PARP7, designed to restore Type I interferon signaling in tumors. It is being developed for patients with cancer as a precision oncology therapeutic candidate.
- RBN-3143 RBN-3143 is a clinical-stage candidate targeting monoPARP biology, developed for cancer and inflammatory diseases as part of Ribon's precision medicine pipeline.
Companies that use Ribon Therapeutics
Customer profileSegments1 record
Ideal customer profiles1 record
Ribon Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Ribon Therapeutics partnerships and signals
Strategic signalScale indicators3 records
Recent moves6 records
Expansion highlights4 records
Ribon Therapeutics competitors and assessment
Company assessmentDirect peers
- Tango Therapeutics: Clinical-stage precision oncology company developing synthetic-lethality and DNA-damage-response therapies. Directly comparable to Ribon as a similarly sized clinical-stage biotech pursuing novel mechanism oncology drugs with pharma partnership optionality.
- Repare Therapeutics: Precision oncology company developing synthetic-lethality-based therapies including a clinical-stage PARG inhibitor. Closely comparable to Ribon in stage, modality (small molecules), oncology focus, and approach of targeting stress/DNA-damage-response pathways.
- Black Diamond Therapeutics: Clinical-stage precision oncology company developing small-molecule kinase inhibitors against allosteric and mutant targets. Comparable in size, stage, and therapeutic approach to Ribon's clinical-stage precision oncology focus.
- Foghorn Therapeutics: Clinical-stage precision oncology biotech targeting chromatin regulatory biology. Comparable to Ribon in stage, modality, and oncology focus with a similarly novel mechanism approach and pharma-backed financing history.
- Nuvalent: Clinical-stage precision oncology company developing kinase inhibitors with a focus on overcoming resistance mutations. Comparable in clinical-stage status, small-molecule modality, and pursuit of differentiated precision oncology targets.
- Erasca: Clinical-stage precision oncology company developing small-molecule inhibitors of the RAS/MAPK pathway. Comparable as a similarly positioned clinical-stage precision oncology biotech with multi-program pipeline.
- Kymera Therapeutics: Clinical-stage biotech developing targeted protein degraders in oncology and immunology. Comparable in stage, indication overlap (oncology and immunology), and small-molecule-based precision medicine approach.
Emerging players
- Recursion Pharmaceuticals: Tech-enabled drug discovery company using AI/ML-driven phenotypic screening to develop precision medicines. Comparable to Ribon in clinical-stage pipeline development but applies a differentiated platform/AI-discovery approach.
Broad incumbents
- Schrödinger: Computational chemistry/drug discovery platform with both internal pipeline and external partnerships. Broadly comparable to Ribon in precision small-molecule drug development and oncology focus, though operating at a much larger and more diversified scale.
- Deciphera Pharmaceuticals: Commercial-stage precision oncology company developing small-molecule kinase inhibitors. Broader incumbent in the same clinical precision-oncology small-molecule space Ribon operates in, with approved product providing established commercial benchmarks.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
Ribon Therapeutics social profiles
Digital presenceRibon Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ribon Therapeutics leadership team
Management profileNumber of profiles
Ribon Therapeutics funding detail
Funding detailFunding overview
Funding rounds7 records
Investors18 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ribon Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ribon Therapeutics
What does Ribon Therapeutics do?
Ribon Therapeutics is a clinical-stage biotechnology company developing precision medicines that target stress response pathways in cancer and inflammatory diseases. Its lead clinical candidates are RBN-2397, a first-in-class PARP7 inhibitor, and RBN-3143, advancing novel monoPARP-targeted therapies toward patients with cancer and inflammatory conditions.
Is Ribon Therapeutics a public or private company?
Ribon Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Ribon Therapeutics founded?
Ribon Therapeutics was founded in 2015. It employs 11 to 50 people.
Where is Ribon Therapeutics based?
Ribon Therapeutics is headquartered in Cambridge, United States, in the North America region.
Who are Ribon Therapeutics's main competitors?
Direct peers on record are Tango Therapeutics, Repare Therapeutics, Black Diamond Therapeutics, Foghorn Therapeutics, Nuvalent, Erasca and Kymera Therapeutics. Recursion Pharmaceuticals is listed as an emerging player. Broad incumbents are Schrödinger and Deciphera Pharmaceuticals.
Does Ribon Therapeutics have an API?
No public API is recorded for Ribon Therapeutics.
What industry is Ribon Therapeutics in?
Ribon Therapeutics's product category is Clinical-stage Oncology Therapeutics. Its primary akta.pro industry code is HLAAADAA, mRNA Therapeutics (vaccines, protein replacement, immuno-oncology). Its NAICS code is 325414 and its SIC code is 2836.